Comparative Pharmacology
Head-to-head clinical analysis: A P L versus HUMEGON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A P L versus HUMEGON.
A.P.L. vs HUMEGON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
A.P.L. (Chorionic Gonadotropin) acts as a luteinizing hormone (LH) agonist, binding to LH receptors in the gonads to stimulate testosterone production in males and ovulation in females.
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
500-1000 mg every 4-6 hours, not to exceed 3000 mg/day in adults.
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (elimination phase); clinical context: requires repeated dosing for sustained effect.
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Renal: 10% unchanged; hepatic metabolism to inactive metabolites excreted in urine and feces (90% combined).
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Category C
Category C
Gonadotropin
Gonadotropin